For years, hormone replacement therapy (HRT) for menopausal women appeared straightforward for the believers. It markedly improved climacteric changes in many organs, including the skin. However, emerging information suggested that combined HRT increased the risks of cardiovascular diseases and invasive breast cancer [1,2]. Many healthcare providers and women were soon impressed by the alarmist lay press regarding the use of these hormones. These pessimistic views were more recently challenged. Indeed, it was demonstrated that the administration of estrogens alone in hysterectomized women did not significantly increase the incidence of coronaropathies and breast cancer [3]. The bulk of recent studies also confirmed that estrogens or estroprogestins effectively suppress the climacteric syndrome and genital atrophy, while significantly decreasing the risk of osteoporotic fractures. The cardiovascular risk appears more prominent in late menopausal HRT users than in early menopause, and the risk of venous thromboembolism can be reduced strongly by using transdermal instead of oral estrogens [4]. Regarding the risk of breast cancer, the additional absolute risk of postmenopausal women using estroprogestins is only 0.08 per 100 women per year, whereas estrogens alone do not increase the risk [3,5].